Table 3.
Multivariate analysis of distant disease-free survival and breast cancer-specific survival for the HR+/HER2− patients, including risk of recurrence risk classification
| DDFS (n = 441) | BCSS (n = 461) | |||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p Value | Hazard ratio | 95% CI | p Value | |
| pT | ||||||
| 1 | 1 | 1 | ||||
| 2 | 1.70 | 0.97–3.00 | 0.065 | 1.52 | 0.91–2.52 | 0.107 |
| 3-4 | 2.30 | 0.86–6.14 | 0.097 | 2.41 | 0.99–4.21 | 0.054 |
| Grade | ||||||
| I | 1 | 1 | ||||
| II | 1.47 | 0.69–3.13 | 0.319 | 1.68 | 0.82–3.42 | 0.156 |
| III | 1.39 | 0.56–3.42 | 0.474 | 2.35 | 1.04–5.35 | 0.041 |
| pN | ||||||
| 0 | 1 | 1 | ||||
| 1 | 1.31 | 0.61–2.81 | 0.492 | 1.22 | 0.61–2.45 | 0.578 |
| 2-3 | 2.27 | 1.04–4.98 | 0.040 | 2.04 | 0.99–4.21 | 0.054 |
| Age | ||||||
| < 55 years | 1 | 1 | ||||
| ≥ 55 years | 0.58 | 0.30–1.11 | 0.102 | 0.63 | 0.36–1.14 | 0.130 |
| Systemic treatment | ||||||
| No | 1 | 1 | ||||
| Tam | 0.99 | 0.48–2.05 | 0.982 | 1.06 | 0.56–2.03 | 0.854 |
| Chemotherapy ± Tam | 0.40 | 0.16–1.02 | 0.055 | 0.48 | 0.21–1.10 | 0.084 |
| ROR score | ||||||
| Low | 1 | 1 | ||||
| Intermediate | 2.25 | 0.77–6.60 | 0.137 | 2.25 | 0.94–5.41 | 0.070 |
| High | 6.82 | 2.62–17.81 | < 0.001 | 4.69 | 2.08–10.55 | < 0.001 |
Abbreviations: BCSS Breast cancer-specific survival, DDFS Distant disease-free survival, HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, ROR Risk of recurrence, TAM Tamoxifen